Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.

de Wit HM, Vervoort GM, Jansen HJ, de Galan BE, Tack CJ

Journal of internal medicine9 Nov 2015Cited by 17 (Europe PMC)

PMID26553486DOI10.1111/joim.12447PepBankPUB-26553486

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and insulin-associated weight gain, liraglutide lowered body weight to a similar extent whether given in the first or the second 26 weeks.
In plain wordsIn adults with type 2 diabetes and insulin-linked weight gain, liraglutide cut weight by about the same amount whether started early or 26 weeks later.
Peptide
Liraglutide
Outcome
No significant changeBody weight change with liraglutide in first versus second 26 weeks
Study
n = 50
Comparator
Liraglutide added in the second 26 weeks (original standard therapy group)
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Body weight change
−4.4 kg
liraglutide in first 26 weeks
Body weight change
−4.3 kg
liraglutide in second 26 weeks
Source sentences
Summary
Addition of liraglutide decreased body weight to a similar extend when given in the first 26 weeks (liraglutide group) or second 26 weeks (original standard therapy group): -4.4 vs. -4.3 kg (difference -0.32 kg, 95% confidence interval -2.2 to 1.6 kg; P = 0.74).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult T2DM patients with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks.
Report a problemFND-2655348601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and insulin-associated weight gain, the HbA1c decrease with liraglutide was similar whether given in the first or the second 26 weeks.
In plain wordsIn adults with type 2 diabetes and insulin-linked weight gain, liraglutide lowered HbA1c by a similar amount whether started early or 26 weeks later.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change with liraglutide in first versus second 26 weeks
Study
n = 50
Comparator
Liraglutide added in the second 26 weeks (original standard therapy group)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.77%
liraglutide in first 26 weeks
HbA1c change
−0.66%
liraglutide in second 26 weeks
Source sentences
Summary
Similar results were also seen in the two groups with regard to decrease in haemoglobin A1c (HbA1c ) (-0.77 vs. -0.66%; P = 0.23) and insulin dose (-28 vs. -26 U day(-1) ; P = 0.32).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult T2DM patients with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks.
Report a problemFND-2655348602
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and insulin-associated weight gain, the insulin dose decrease with liraglutide was similar whether given in the first or the second 26 weeks.
In plain wordsWith insulin-linked weight gain, liraglutide lowered the insulin dose by a similar amount whether started early or 26 weeks later.
Peptide
Liraglutide
Outcome
No significant changeInsulin dose change with liraglutide in first versus second 26 weeks
Study
n = 50
Comparator
Liraglutide added in the second 26 weeks (original standard therapy group)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Insulin dose change
−28 U/day
liraglutide in first 26 weeks
Insulin dose change
−26 U/day
liraglutide in second 26 weeks
Source sentences
Summary
Similar results were also seen in the two groups with regard to decrease in haemoglobin A1c (HbA1c ) (-0.77 vs. -0.66%; P = 0.23) and insulin dose (-28 vs. -26 U day(-1) ; P = 0.32).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult T2DM patients with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks.
Report a problemFND-2655348603
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and insulin-associated weight gain, 22% of patients in both groups could discontinue insulin after liraglutide.
In plain wordsIn adults with type 2 diabetes and insulin-linked weight gain, about one in five patients on liraglutide could stop insulin, in both groups.
Peptide
Liraglutide
Outcome
Not applicablePatients able to discontinue insulin
Study
n = 50
Comparator
Liraglutide added in the second 26 weeks (original standard therapy group)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Patients able to discontinue insulin
22%
both groups
Source sentences
Summary
In both groups, 22% of patients could discontinue insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult T2DM patients with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks.
Report a problemFND-2655348604
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and insulin-associated weight gain, continuing liraglutide until 52 weeks sustained the effect on body weight.
In plain wordsIn adults with type 2 diabetes and insulin-linked weight gain, the weight loss with liraglutide was kept up to 52 weeks.
Peptide
Liraglutide
Outcome
DecreaseBody weight at 52 weeks of continued liraglutide
Study
n = 50
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 52 weeksAs given in this study (human).
Source sentences
Summary
Continuation of liraglutide until 52 weeks led to sustained effects on body weight, HbA1c and insulin-dose requirements.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult T2DM patients with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks.
Report a problemFND-2655348605
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and insulin-associated weight gain, continuing liraglutide until 52 weeks sustained the effect on HbA1c.
In plain wordsIn adults with type 2 diabetes and insulin-linked weight gain, the HbA1c improvement with liraglutide was kept up to 52 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c at 52 weeks of continued liraglutide
Study
n = 50
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 52 weeksAs given in this study (human).
Source sentences
Summary
Continuation of liraglutide until 52 weeks led to sustained effects on body weight, HbA1c and insulin-dose requirements.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult T2DM patients with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks.
Report a problemFND-2655348606
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and insulin-associated weight gain, continuing liraglutide until 52 weeks sustained the effect on insulin-dose requirements.
In plain wordsIn adults with type 2 diabetes and insulin-linked weight gain, the lower insulin need with liraglutide was kept up to 52 weeks.
Peptide
Liraglutide
Outcome
DecreaseInsulin dose requirement at 52 weeks of continued liraglutide
Study
n = 50
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 52 weeksAs given in this study (human).
Source sentences
Summary
Continuation of liraglutide until 52 weeks led to sustained effects on body weight, HbA1c and insulin-dose requirements.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult T2DM patients with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks.
Report a problemFND-2655348607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.